Citeline's expert analysts regularly produce reports on key aspects of the industry, new therapy developments and trends. Enjoy free access to these insights by downloading our latest whitepapers below.
An analysis into the current clinical development landscape for Parkinson's disease. Is there hope for potential new therapies in the near future and beyond?Download
An examination into the landscape of the pharmaceutical industry's new drug development and clinical trial activity in heart failure.Download
An exploration of the key sponsors of type 2 diabetes trials that enroll pediatric patients, the trial locations, and whether or not these
trials are only for postmarketing requirements.
Changing Tides in Hepatitis C Virus (HCV) Treatment: The New Wave of HCV Drugs and Effects on Enrollment Trends
An exploration of enrollment trends in HCV trials, specifically the experience of the most active industry
sponsors and the effect that interferon and antivirals has had on recruitment rates over time.
Recent Trends in Personalized Medicine: Increasing Clinical Use and Impact of Pharmacogenomic and Epigenetic Biomarkers in Oncology
An examination of oncology clinical trials identifying, testing or using pharmacogenomic (PGX) biomarkers to either select or stratify patients.Download
Is Achieving Trial Success a Roll of the Dice? Dissecting Trials with Positive Outcomes to Identify Strategies for Success.
An examination of Autoimmune/Inflammation clinical trial-level success rates to date. This report tries to identify strategies that may correlate with success.Download
An analysis of the landscape of drug development for rare diseases, including the density of development by phase, developing company and disease, including a discussion on some of the reasons drug developers are going after rare diseases.Download
An examination of late stage dyslipidaemia research to identify current trends and determine which near-term compound look the most encouraging.Download
A review of the current landscape of HIV vaccine research for prevention and treatment, to determine if the field has rebounded from the setbacks of the STEP and ORVACS 002 trials. Trends in prophylactic and therapeutic vaccine clinical research are also revealed. Is gene therapy research a potential alternative to a therapeutic vaccine?Download
A profile of the drugs and clinical trials making up the current SLE landscape. How is Benlysta shaping the future of SLE drug development and providing a window onto the continued unmet need for many patients suffering from this diverse disease?
Rising to the Challenge:An Analysis of the Influenza Vaccine Landscape in Response to the Swine Flu Pandemic
Citeline evaluates the methods manufacturers pursued in response to the swine flu pandemic, with an analysis of alternate manufacturing methods and routes of administration. Have the major players in influenza vaccines shifted?
Citeline examines the clinical trials activity for MS looking to discern any trends or paradigm shifts that reflect the patient segments being investigated.Download
Immunotherapeutic drugs took center stage this year at The 49th Annual ASCO Meeting. This report provides an overview of the trials reported, looks at some of the individual drug highlights and analyses the distribution of investigators in those trials.Download
Citeline explores the current drug development landscape, the mechanisms of action, biomarkers, and top sponsors that are shaping Alzheimer’s treatment into the next three years.Download
Citeline analyzes benchmark data for oncology trials whose protocols include or omit objectives of identifying prognostic or predictive biomarkers, or endpoints involving biomarkers to assess efficacy or toxicity.Download
Cardiovascular safety is a critical factor in T2D new drug research. This report outlines the mixed successes sponsors have had while navigating new FDA requirements.Download